AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.
Zacks
More News
3 Things You Need to Know If You Buy Pfizer Stock Today
Key PointsInvestors won't start seeing the fruits of Pfizer's current efforts for several more years...
Nasdaq News: Markets
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties.read more...
Benzinga
Pfizer (PFE) Up 12.4% Since Last Earnings Report: Can It Continue?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Pfizer's Pipeline Strategy Centers on Obesity and Oncology
PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.
Zacks
Why Did PFE, GTLB, COP Stocks Jump To 52-Week Highs Today?
Pfizer, GitLab, and Conoco Phillips shares surged to 52-week highs on Wednesday amid a series of positive company catalysts and optimistic Wall Street coverage.
Stocktwits
Should You Buy Pfizer Stock Below $30?
Key PointsPfizer's financial results aren't great, and the company will face important patent cliffs relatively soon...
Nasdaq News: Markets
2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now
Key PointsBristol Myers Squibb and Pfizer have both seen solid gains in their share prices this year...
Nasdaq News: Markets
Why Did PFE, MMED, DE Stocks Surge To 52-Week Highs Today?
Pfizer gained on vaccine and oncology growth, MiniMed on strong earnings, and Deere on AI-driven agriculture.
Stocktwits
From Padcev to PF-08634404: Pfizer's Oncology Growth Push
PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.